title: A new combination therapy in severe acute pancreatitis--hyperbaric oxygen plus 3-aminobenzamide: an experimental study.
abstract: OBJECTIVE
  This study was designed to evaluate effects of hyperbaric oxygen (HBO) plus 3-aminobenzamide (3-AB) cotreatment on tissue oxidative stress parameters (TOSp), tissue histopathology scores (THSc), and bacterial translocations (Bact-Trans) in an experimental model of severe acute pancreatitis (AP).
  
  
  METHODS
  Seventy-five Sprague-Dawley rats were randomized into 5 groups. Group 1 received sham. Severe AP was induced by intraductal taurocholate infusion and then group 2 received saline, group 3 received 3-AB, group 4 received 3-AB plus HBO, and group 5 received HBO. 3-Aminobenzamide (10 mg/kg per day, once daily, intraperitoneal) and saline (1 mL/kg) were started right after the induction, whereas HBO (2,8 atm pressure, BID, 90 minutes each) was started at the sixth hour. The rats were euthanized at the 54th hour, and TOSp, THSc, and Bact-Trans were studied.
  
  
  RESULTS
  In treatment groups 3 and 5, Bact-Trans (P < 0.05, P < 0.05), TOSp (P < 0.05, P < 0.05), and THSc (P < 0.001, P < 0.001) were significantly lower than controls. In addition to these findings, group 4 (cotreatment) showed the most significant effect on Bact-Trans and THSc (P < 0.001, P < 0.001) and also better in TOSp (P < 0.02).
  
  
  CONCLUSIONS
  Poly(ADP-ribose) polymerase inhibition by 3-AB and HBO treatment alone was effective in the course of severe AP, and favorable with cotreatment because of the improved cascades of inflammatory process by different aspects.
authors.affiliation: From the *Department of Intensive Care, Internal Medicine, Trakya University Faculty of Medicine, Edirne; Departments of †Geriatrics, and ‡Intensive Care, Internal Medicine, Dokuz Eylul University Faculty of Medicine, Izmir; §Department of Surgery, Guven Hospital, Ankara; ∥Department of Anatomy, Dokuz Eylul University Faculty of Medicine, Izmir; and Departments of ¶Pathology, #Internal Medicine, **Intensive Care, Internal Medicine, and ††Infection Disease, Gulhane School of Medicine, Ankara, Turkey.
authors.forename: Volkan
authors.initials: V
authors.lastname: Inal
authors.forename: Mehmet Refik
authors.initials: MR
authors.lastname: Mas
authors.forename: Ahmet Turan
authors.initials: AT
authors.lastname: Isik
authors.forename: Bilgin
authors.initials: B
authors.lastname: Comert
authors.forename: Sezai
authors.initials: S
authors.lastname: Aydn
authors.forename: Nukhet
authors.initials: N
authors.lastname: Mas
authors.forename: Mehmet Salih
authors.initials: MS
authors.lastname: Deveci
authors.forename: Ilker
authors.initials: I
authors.lastname: Tasci
authors.forename: Levent
authors.initials: L
authors.lastname: Yamanel
authors.forename: Esref
authors.initials: E
authors.lastname: Cinar
authors.forename: Mehmet Tahir
authors.initials: MT
authors.lastname: Unal
mesh_terms: D000208:Acute Disease; D000818:Animals; D018988:Bacterial Translocation / Q000187:drug effects; D001549:Benzamides / Q000494:pharmacology*; D003131:Combined Modality Therapy; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006931:Hyperbaric Oxygenation; D008297:Male; D018384:Oxidative Stress / Q000187:drug effects; D010179:Pancreas / Q000187:drug effects* / Q000378:metabolism / Q000382:microbiology / Q000473:pathology; D010195:Pancreatitis / Q000139:chemically induced / Q000378:metabolism / Q000382:microbiology / Q000473:pathology / Q000628:therapy*; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011065:Poly(ADP-ribose) Polymerases / Q000378:metabolism; D012720:Severity of Illness Index; D013656:Taurocholic Acid; D013997:Time Factors
chemical_list: D001549:Benzamides; D004791:Enzyme Inhibitors; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D013656:Taurocholic Acid; C025160:3-aminobenzamide; D011065:Poly(ADP-ribose) Polymerases